Complete response to afatinib in lung adenocarcinoma of epidermal growth factor receptor exon-19 deletion mutation and disease recurrence on drug discontinuation

2018 ◽  
Vol 9 (4) ◽  
pp. 191 ◽  
Author(s):  
Emmanuel James ◽  
Rashmi Kumari ◽  
K Pavithran
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Complete Response ◽  
Disease Recurrence ◽  
Drug Discontinuation ◽  
Exon 19 Deletion ◽  
Epidermal Growth ◽  
Exon 19

Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer

Tumor Biology ◽  
2015 ◽  
Vol 36 (12) ◽  
pp. 9251-9258 ◽  
Author(s):  
Hongwei Li ◽  
Xiaqin Zhang ◽  
Jianzhong Cao ◽  
Pengcheng Su ◽  
Jianhong Lian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Exon 19 Deletion ◽  
Epidermal Growth ◽  
Exon 19

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. TPS8123-TPS8123 ◽  
Author(s):  
Tony Mok ◽  
Kazuhiko Nakagawa ◽  
Rafael Rosell ◽  
Yi Long Wu ◽  
Carl Trygstad ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Phase Ii ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Open Label ◽  
Exon 19 Deletion ◽  
Epidermal Growth ◽  
Exon 19

TPS8123 Background: D is an orally available, potent and selective irreversible small molecule inhibitor of all catalytically active members of the HER (human epidermal growth factor receptor) family tyrosine kinases that has shown activity in preclinical studies on EGFR mutant cell lines, including those resistant to G. In a phase II trial of NSCLC pts who received 1st-line D, 75.6% of 45 pts with confirmed EGFR exon 19 or 21 sensitizing mutations (m) experienced a partial response (PR). The median progression-free survival (PFS) was 18.2 mo, and the PFS rate at 1 yr was 76.5% (preliminary data; Mok et al APLCC 2012). Methods: Based on the phase II data, a phase III randomized, open label trial (ARCHER 1050; NCT01774721) was designed to compare the efficacy of 1st line D with G in pts with adv EGFR m-positive NSCLC. Eligible pts (N=440) have pathologically confirmed stage IIIB/IV NSCLC with at least one activating EGFR m, either exon 19 deletion or exon 21 L858R m. Concurrent m in exon 20 T790M is permitted. Pts must have radiologically measurable disease, ECOG PS 0–1 and no prior systemic therapy. Pts will be randomized (1:1) to receive D 45 mg or G 250 mg orally once daily. The primary endpoint is PFS by Independent Radiologic Review. Secondary endpoints include PFS by investigator assessment, overall survival (OS), OS at 30 mo, best overall response, duration of response, and safety and tolerability. Pt-reported outcomes (HRQoL and disease/treatment-related symptoms) were also assessed. Randomization will be stratified by race (Japanese vs mainland Chinese vs other East Asian vs nonEEast Asian), and EGFR m status (exon 19 deletion vs exon 21 L858R m). A minimum of 268 PFS events is required for 90% power to detect a PFS improvement of ≥50% in D vs G recipients using the intent-to-treat (ITT) analysis population (HR ≤0.667). A significant (0.025 significance level) 1-sided stratified log-rank test for PFS at the final PFS analysis will be indicative of a positive study outcome. An interim analysis is planned to assess safety and whether early discontinuation of the trial is required for futility. Clinical trial information: NCT01774721.

scholarly journals Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion

2011 ◽  
Vol 6 (1) ◽  
pp. 199-202 ◽  
Author(s):  
Eckart Laack ◽  
Ronald Simon ◽  
Marc Regier ◽  
Birte Andritzky ◽  
Pierre Tennstedt ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Strong Association ◽  
Growth Factor Receptor ◽  
Adenocarcinoma Of The Lung ◽  
Exon 19 Deletion ◽  
Epidermal Growth ◽  
Exon 19

scholarly journals Erratum to: Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer

Tumor Biology ◽  
2015 ◽  
Vol 36 (9) ◽  
pp. 7333-7334
Author(s):  
Hongwei Li ◽  
Xiaqin Zhang ◽  
Jianzhong Cao ◽  
Pengcheng Su ◽  
Jianhong Lian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Exon 19 Deletion ◽  
Epidermal Growth ◽  
Exon 19

scholarly journals Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing

BMC Cancer ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Luisella Righi ◽  
Alessandra Cuccurullo ◽  
Simona Vatrano ◽  
Susanna Cappia ◽  
Daniela Giachino ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Exon 19
Sign in / Sign up

Export Citation Format

Share Document